MedPath

A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Skin to Recover After a Peeling in the External Genital Area of Women

Phase 4
Completed
Conditions
Skin Recovery
Interventions
Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Other: Semisolid vaseline
Registration Number
NCT03853512
Lead Sponsor
Bayer
Brief Summary

In this study, researchers want to learn more about the effect of dexpanthenol dermal spray on skin recovery after a dermatological procedure (peeling) in the intimate area of women.

After the peeling, participants will return within 3 weeks for 4 visits to the study center to investigate the skin conditions such redness, irritation, softness and possible side effects. In addition, study participants will be asked about their general acceptance of dexpanthenol dermal spray.

Detailed Description

The primary objective is to evaluate the efficacy of the test product to aid skin recovery after peeling in the female intima and inguinal region.

Secondary objectives comprise clinical efficacy with respect to skin hydration, softness, vitality, appearance etc. and skin recovery, consumer judgement of product performance and acceptability, and safety.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
33
Inclusion Criteria
  • Phototypes I and II according to the Fitzpatrick scale;
  • Participants willing to have peeling in the genital area to improve the general appearance of the skin and bleaching of spots.
Read More
Exclusion Criteria
  • Pathologies and/or skin injuries, such as psoriasis, sensitive skin, skin cancer, atopic dermatitis or other medical criteria to be considered at the time of evaluation
  • Hyperpigmentation in the test area that interfere with the evaluation of possible reactions (vascular malformations, scars, increase of pilosity and large amount of nevi)
  • Pathologies and/or active skin injuries (local and/or disseminated) in the evaluation area
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Women_Inguinal side BAY207543BAY207543 (Bepanthol, Bepantol® Derma Spray)Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with BAY207543 will be investigated.
Women_Inguinal side BAY207543Semisolid vaselineAdult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with BAY207543 will be investigated.
Women_Inguinal side VaselineBAY207543 (Bepanthol, Bepantol® Derma Spray)Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with the vaseline will be investigated.
Women_Inguinal side VaselineSemisolid vaselineAdult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with the vaseline will be investigated.
Primary Outcome Measures
NameTimeMethod
Transepidermal water loss by TEWL probeUp to 23 days

The transepidermal water loss (TEWL) is measured in g m2 h-1 with a Tewameter TM300.

Secondary Outcome Measures
NameTimeMethod
Skin properties of the participantsUp to 23 days

Investigators assess various skin properties of the participants with a questionnaire (each scored from 1 to 5), resulting in an overall efficacy score from 12 to 60 (a higher score represents higher efficacy).

Treatment satisfactionUp to 23 days

Participants assess their treatment satisfaction with a questionnaire consisting of 19 items (each item is scored from 1-5) resulting in a score range of 19 to 95 (a higher score represents better treatment satisfaction).

Product evaluationUp to 23 days

Participants assess their sensorial perception of different product attributes (e.g. smell, absorption) with a questionnaire consisting of 6 items (each item is scored from 1-5) resulting in a score range from 6 to 30 (a higher score represents higher product satisfaction).

Number of adverse events by gynecological evaluationUp to 23 days
Severity of adverse events by dermatological evaluationUp to 23 days
Number of adverse events by dermatological evaluationUp to 23 days
Severity of adverse events by gynecological evaluationUp to 23 days

Trial Locations

Locations (1)

Medcin Instituto da Pele

🇧🇷

Sao Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath